Transmedics Group (TMDX) News
What's actually happening: chronological and provenance-stamped. News is context, not a signal.

Shareholders are encouraged to contact the firm to discuss their rights and options at no cost or obligation. We would handle any matter on a contingent fee basis, whereby you would not be responsible for out-of-pocket p…

TransMedics Group is reiterated as a 'strong buy' due to compelling valuation and significant upside potential tied to multi-organ platform expansion. TMDX's 2027 catalysts include ENHANCE Heart, DENOVO Lung, CHOPS, OCS …

TransMedics (TMDX) reached a significant support level, and could be a good pick for investors from a technical perspective. Recently, TMDX broke through the 200-day moving average, which suggests a long-term bullish tre…

TransMedics Group Inc. demonstrates accelerating revenue growth, improved service margins, and market share gains in the recent quarter. TransMedics raised full-year revenue guidance to $764-774 million, with organic gro…

TransMedics raised 2026 revenue guidance to $764 million to $774 million. Third-quarter revenue reached $203 million, up 41% year over year.…

TransMedics (TMDX) reached a significant support level, and could be a good pick for investors from a technical perspective. Recently, TMDX broke through the 20-day moving average, which suggests a short-term bullish tre…

From a technical perspective, TransMedics (TMDX) is looking like an interesting pick, as it just reached a key level of support. TMDX recently overtook the 50-day moving average, and this suggests a short-term bullish tr…

TransMedics Group NASDAQ: TMDX raised its full-year revenue outlook after reporting record third-quarter revenue and transplant case volume, as gains in its liver and heart businesses helped offset a decline in U.S. dece…

Three stocks are seeing unusual options activity following their quarterly earnings reports: DraftKings Inc (NASDAQ:DKNG), TransMedics Group Inc (NASDAQ:TMDX), and Omada Health Inc (NASDAQ:OMDA).…

While the top- and bottom-line numbers for TransMedics (TMDX) give a sense of how the business performed in the quarter ended September 2026, it could be worth looking at how some of its key metrics compare to Wall Stree…

TransMedics Group, Inc. (TMDX) Q3 2026 Earnings Call Transcript…

TransMedics (TMDX) came out with quarterly earnings of $0.51 per share, beating the Zacks Consensus Estimate of $0.27 per share. This compares to earnings of $0.66 per share a year ago.…

Strong Revenue Generation Drives Increase in Full-Year 2026 Guidance; Recent Progress Positions Company for Continued Growth with Several Near- and Mid-Term Catalysts ANDOVER, Mass., Nov. 5, 2026 /PRNewswire/ -- TransMed…

TMDX's OCS technology, robust pipeline and global expansion support growth prospects, but margin pressures and rising investments remain key concerns.…

Looking beyond Wall Street's top-and-bottom-line estimate forecasts for TransMedics (TMDX), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended Septe…

LOS ANGELES--(BUSINESS WIRE)---- $TMDX--TMDX Investors Have Opportunity to Join TransMedics Group, Inc. Fraud Investigation with SBS Law.…

ANDOVER, Mass., Oct. 30, 2026 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, an…

ANDOVER, Mass., Oct. 29, 2026 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, an…

Reliable, high-performance connectivity will support time-critical transport and monitoring of donor organs for transplants aboard 22 Embraer Phenom 300E aircraft Reliable, high-performance connectivity will support time…

ANDOVER, Mass., Oct. 22, 2026 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart and…

On October 21, 2026, TransMedics Group Inc (TMDX) shares fell by 3.1%, bringing the current price to $72.40. This decline is notable within a 52-week range of $…

TransMedics Group (NASDAQ: TMDX - Get Free Report) and iRhythm Technologies (NASDAQ: IRTC - Get Free Report) are both mid-cap healthcare companies, but which is the better investment? We will contrast the two businesses …

On October 01, 2026, TransMedics Group Inc (TMDX) shares fell 5.8%, closing at $78.64. The stock's performance over the past year has been challenging, with a 5…

Shareholders are encouraged to contact the firm to discuss their rights and options at no costor obligation. We would handle any matter on a contingent fee basis, whereby you would notbe responsible for out-of-pocket pay…

NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), announces that KSF has commenced an investigation in…

ANDOVER, Mass., Sept. 10, 2026 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), the global leader in portable warm perfusion for donor organs for transplantation, today announced the appointment of…
Kept in their own lane. A press release is the company talking, not reporting.
No upcoming events in the feeds.

